Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Daiichi Sankyo’s Big-Seller Hopeful DS-8201 Filed in Japan
Daiichi Sankyo said on September 9 that it has submitted a new drug application in Japan for its hoped-to-be-blockbuster DS-8201 (trastuzumab deruxtecan), a HER2-targeting antibody drug conjugate (ADC), for the treatment of HER2-positive metastatic breast cancer. The filing is based…
To read the full story
Related Article
- Daiichi Sankyo’s Enhertu Hits Japan Market for Breast Cancer
May 26, 2020
- Daiichi Sankyo’s DS-8201 Hits Primary Target in PII Gastric Cancer Trial
January 28, 2020
- Daiichi Sankyo, AZ Nab US Nod for ADC Enhertu in Breast Cancer
December 24, 2019
- FDA Gives Priority Status to Daiichi Sankyo/AZ’s HER2-Tageting ADC
October 18, 2019
- DS-8201 Delivers in PII Breast Cancer Study: Daiichi Sankyo/AZ
May 9, 2019
BUSINESS
- Chugai Files Gazyva for Idiopathic Nephrotic Syndrome in Japan
May 15, 2026
- Astellas, MSD File Padcev-Keytruda for Cisplatin-Eligible MIBC in Japan
May 15, 2026
- Sumitomo Notches Record Profit on Strong North America Growth
May 14, 2026
- Takeda’s FY2025 Sales Fall 1.7% on Vyvanse Generic Erosion
May 14, 2026
- Shionogi Nets 4th Straight Year of Record Earnings on Torii Deal, HIV Royalties
May 13, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…